camonsertib + talazoparib

Camonsertib + talazoparib is an experimental combination therapy being studied for the treatment of advanced solid tumors, particularly those harboring DNA damage response (DDR) alterations such as BRCA1, BRCA2, and ATM mutations. Camonsertib is a potent, selective oral inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), a kinase involved in cellular responses to DNA damage. Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor, which impairs the repair of single-strand DNA breaks. The rationale for this combination lies in synthetic lethality: ATR inhibition by camonsertib exacerbates DNA repair defects introduced by PARP inhibition, promoting cancer cell death, especially in tumors with homologous recombination deficiencies. This approach may yield activity in tumors resistant to PARP inhibitors and platinum agents. Early-phase clinical studies (TRESR, ATTACC) have found that the combination can be active across several tumor types, with a tolerable safety profile using low-dose, intermittent regimens. Common toxicities include anemia, neutropenia, and thrombocytopenia[1][2][3][5][7][9].

Other names

camonsertib + talazoparib